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Article
“Coming Out”: Stigma,
Reflexivity and the Drug
Researcher’s Drug Use
Anna Ross1, Gary R. Potter2, Monica J. Barratt3,4 ,
and Judith A. Aldridge5
Abstract
Some personal experience of illicit drug use undoubtedly exists within the population of academic drug
researchers. But it is rarely acknowledged, and even more rarely reflected upon, in their published
work. This is understandable: criminal, professional and social sanctions may follow public admission of
illicit activities. However, to not “come out” seems contrary to some core academic principles, such as
transparency in data collection and reflexivity in the research process. Coming out may present
researchers with an opportunity for improving knowledge of, and policies toward, drug use. In this
article, we identify reasons for and against the public disclosure of drug use and the impact of such
disclosure across a range of spheres, including research, teaching, policy influence and private lives.
Reasons against coming out include the risks of undermining professional reputations and hence the
ability to contribute to academic and policy debates, the threat of criminal justice sanctions, and
impacts on loved ones. However, coming out can have academic benefit (i.e., improving our under-
standing of drugs, of people who use drugs, and of drug research) and contribute to activist goals
(e.g., de-stigmatization of drug use and demarginalization of people who use drugs). Both the risks and
benefits of public drug use disclosure have implications for how research and researchers may influ-
ence drug policy. Two key themes, stigma and reflexivity, underpin the discussion. We do not conclude
with clear recommendations for drug-using drug researchers; to come out or to not come out is a
personal decision. However, we argue that there is clear merit to further open discussion on the role
of disclosure and reflection on personal drug use experience among those working in drug research
and drug policy—where such reflection is relevant and where such researchers feel able to do so.
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Should drug researchers who have direct personal experience of taking illegal drugs1 discuss these
experiences in their work? This question stirred discussion and debate at the 2016 annual conference of
the International Society for the Study of Drug Policy (ISSDP) in Sydney, Australia. The idea that drug
researchers2 might themselves also take drugs is certainly not new, but the discussion in Sydney was
noteworthy for a few reasons. First, the debate emerged “in session,” rather than (just) as a feature of
informal chats or “corridor talk” (Harris, 2015, p. 1697). Second, a substantial number of conference
attendees—most active researchers and drug policy experts—contributed to these discussions, both
those with and those without personal experience of illegal drug use. Third, we discerned a strong
sense that this debate should—now—be documented in the academic literature, rather than ignored as
has, with a few notable exceptions, so far been the case. After a further year of discussion and
reflection, both among we four authors and with colleagues working in the drug field around the
world, we took the topic to the 2017 ISSDP conference in Aarhus, Denmark, in the form of a workshop
on the benefits and risks of publicly disclosing personal drug use. These discussions with colleagues in
various forums inform the substance of this article: a consideration of the arguments for and against
drug researchers “coming out” about and reflecting on their own experiences of drug use.
The trigger, in Sydney, was a paper that raised the question of “experiential knowledge” and its
formal and informal roles in shaping data collection and analysis (Ross, 2016). Inputs into drug policy,
like so many other policy areas, are increasingly performed within an “evidence-based” paradigm
(Lancaster, 2016; O’Gorman et al., 2016). What role, then, does personal experience play? Ross’s
paper raised two questions that a number of other attendees recalled pondering in the early days of their
careers: are experts at least partly impaired in their understanding of drug use if they do not have that
key component of expertise—personal experience; and, can—or should—researchers be open about
their own personal experiences of drug use and the role these experiences have played in shaping their
own research? Of course, there will be many drug researchers who have considered the question of
coming out: this “dilemma” is neither rare nor new.
However, the dilemma remains unresolved—and largely undiscussed—within the literature. We
argue that this absence is problematic. That some people working in the drugs field have been—or
currently are—drug takers themselves is evident from the literature, implicit in prevalence data, and
confirmed by our own discussions with colleagues around the world. But this relevant personal
experience is rarely acknowledged, and even more rarely reflected upon, in published work or public
discussion. On one level, this is understandable: stigma, and social, professional and criminal sanc-
tions, may all follow public admission of illicit activities. However, to not “come out” arguably falls
short on several methodological and ethical principles. At best, this silence removes an important body
of evidence from consideration: the researcher’s own background knowledge of the object being
studied. At worst, it exacerbates the othering and marginalization of (particularly some populations
of) drug takers. On any analysis, it goes against the academic ideals of reflexivity, openness and
integrity, and is a missed opportunity for improving our knowledge of, and policies toward, drugs.
And while there is an argument that the scientific principle of objectivity is undermined by researcher
drug use, the counter-argument suggests that staying silent about drug use when it does occur merely
hides an aspect of the researcher’s positionality from the research audience. For researchers who value
reflexivity, therefore, silence on this issue is bad science.
Aware of these tensions, our aim in this article is to scope out the opportunities and the challenges of
going public or staying silent about personal experiences of prohibited substance use by researchers
who work in the drugs field. We seek to consider critically the functions of drug-taking for researchers
and the research process, and the potential impact of public disclosure of drug-using status on our
scientific understanding of drug use, on the development of drug policy, on the discipline and on our
universities, and on the professional and personal lives of drug-using drug researchers.
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Approach
In this article we discuss a series of issues relating to coming out, drawing on the published literature,
empirical data and our own interpretations and reflections. We draw on both informal discussions and
our 2017 ISSDP conference workshop “Are we ready to come out? Discretion, disclosure, identity and
the drug researcher’s drug use.” Approximately 30 delegates attended, from across Europe, North
America and Australasia, and with a variety of histories and experiences within drug research and drug
policy. The workshop encouraged us to refine our themes and structure the discussion we offer in this
article. Alongside the formal and informal conversations and experiences outlined above, we consid-
ered examples where researchers have come out in the literature. From across these various sources,
key themes emerged and are discussed here. We begin with a scoping of key concepts used in this
article, including the metaphor of “coming out” and the concept of reflexivity. Then, we consider the
extent of drug use among drug researchers. The main part of the article explores the arguments for and
against public disclosure of drug use by drug scholars, with particular reference to the scientific
process and engagement in policy and politics. Our discussion then focuses on different parameters
of the debate, including reflections on privilege and intersectionality as they pertain to self-disclosure.
Key Concepts: “Coming Out” and Reflexivity
In writing about the public self-disclosure of drug use by drug-using researchers, we have followed the
usage of the term “coming out” that is widespread within drug cultures3. The phrase “coming out of the
closet” was thought to be first associated with disclosure of gay/lesbian identity in the 1960s: Travers
Scott (2018) identifies the source metaphor as “a skeleton in the closet”—“a secret that is hidden due to
its social stigma” (p. 146). To apply this phrase to drug use is to allude to the similar experience of drug
use as a secret or hidden identity and of coming out as a “drug user” as being a challenge to the
fundamental logic of binary thinking in Western (heteronormative) culture. We point to queer theorists
such as Sedgwick (1990), McDonald (2013) and Adams (2010) for a theoretical discourse developed
around sexuality and identity that may offer some useful and relevant insights applicable to a “drug
user” identity, but we do not seek to explore that particular line of thinking in this current article
beyond recognizing that “coming out” is far from straightforward. For example, Adams (2010) writes
that the closet metaphor creates the paradoxical situation whereby “coming out of the closet” (about
one’s gay identity) is considered “a discrete, linear process with a definitive end” while simultaneously
being “an inescapable, ever-present process,” assumed to be necessary, important and healthy. Coming
out can also be dangerous. Adams eloquently describes the paradoxical bind applicable to people with
a stigmatized concealed identity, produced by the combined presumptions underlying the closet
metaphor. Drug-using drugs researchers can find themselves in a similar bind, as we argue later in
this article.
The appropriation of the coming out metaphor outside of its origins is not without critique (Travers
Scott, 2018) and the parallels between identifying as LGBTIQþ and identifying as a person who uses
drugs should be treated with caution (see also Devenot, 2016, and Kaywin, 2016, as it pertains to
psychedelic identities, discussed later). The definition we use in this article is that coming out con-
stitutes a public admission of illicit drug use in the course of professional work, while acknowledging
the fluidity of parameters around these practices. In the later section “parameters of coming out,” we
work through the various aspects of the process and their implications, noting that such decisions and
their outcomes rest heavily upon who is coming out, what they are coming out about, who they are
coming out to, what they hope to achieve, and the intersections of these differences.
A concept very much related to coming out is reflexivity. Traditional Cartesian models of scientific
inquiry follow the belief that knowledge exists outside the knower—the atomistic model of knowing.
However, phenomenological and non-positivist approaches tend to incorporate some understanding
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that knowledge cannot be separated from the knower. For example, feminist epistemological
approaches have developed the concept of situated knowers (Haraway, 1988)—that there are some
experiences that cannot be known by others because of systemic and structural differences. This
concept can be expanded to social position and other systemic differences in society (Ettore, 2017;
Fricker, 2013). Broadly speaking, the acknowledgment of where the knower is in space and time will
impact the research development and findings (Grasswick, 2018; Harding, 1986; Hartsock, 1987).
Situated knowledge can be incorporated into research through the reflexive process by exposing the
“hidden ethnography” (Blackman, 2007): by bringing to the fore aspects of the research that previously
remained invisible due to fears about legitimacy and researcher bias. Of specific relevance to our
article, Lumsden (2019) notes that by practicing reflexivity “we acknowledge that we cannot be
separated from our biographies” (p. 16). Of particular relevance here is self reflexivity (McDonald,
2013), which relates to accounts of how the researcher’s social positioning locates them within their
field of study, and in particular, how their fluid and changing identities interact with the fluid and
changing identities of those in their research with whom they interact. Later work by Blackman (2016)
illustrates the utility of self-reflexivity in which “the researcher locates themselves in the research
context, and offers an account of the feeling and play of interaction that explains how data was
generated, selected and theorised” (p. 65).
We will draw on the concepts of situated knowledge and self-reflexivity as we consider the issue of
public disclosure of the drug researcher’s drug use. In doing so, we also note the critiques of reflex-
ivity. It is not necessarily in itself always positive, nor does practicing reflexivity necessarily ensure
better research or more positive outcomes from research. Some have cautioned that by moving our
gaze back to ourselves as researchers, we may end up privileging our own epistemologies ahead of
those about whom we are writing, or worse, producing naval-gazing texts (Blackman, 2016; Lumsden,
2019). We do not argue in this article that public disclosure of drug use is a panacea that guarantees
reflexivity in research. We do argue that, in some cases at least, deeper reflection and conversation on
disclosure of drug use would be beneficial both for academic rigor and for challenging the stigma
associated with drug use. Either way, further work of accounting for the researcher’s social location
and how it intersects with various parts of the research process is also required.
Drug use in the Drug Research Community
We know that there are some drug researchers with at least some personal drug use experience. We do
not know how prevalent such experiences are, but to assume they are negligible would be naı̈ve:
around 5% of the global adult population used drugs at least once in 2015 (United Nations Office on
Drugs and Crime, 2017). We might anticipate a higher-than-average level of drug use experience
among professional drug researchers for various reasons. Although “problem” drug use is often
associated with disadvantaged members of society, “recreational” drug use is relatively common
among middle-class and professional groups in the economically advanced countries from which
academic researchers are disproportionately drawn. For example, in Australia’s most recent national
household survey, “socioeconomic status and education had little influence on a person’s recent
cannabis use” (p. 62) and “people in lowest socioeconomic areas were less likely to use cocaine and
ecstasy than people in highest socioeconomic areas” (Australian Institute of Health and Welfare, 2017,
p. 96). Moreover, academics, particularly social scientists, often research topics with which they have a
personal interest and experience.
Historically, academic writings that have acknowledged their authors’ own use of illicit4 drugs,
although rare, date back at least to the 1950s and 1960s, when academics openly admitting to drug use
was a significant part of the broader counter-culture movement of the period. Examples as varied as
Aldous Huxley (1954, Doors of Perception), Howard Becker (1963, Outsiders: Studies in the sociol-
ogy of deviance), Timothy Leary et al. (1964, The Psychedelic Experience) and Alexander Shulgin
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(1992, PiHKAL: A chemical love story) are particularly well known. These and other examples of
public disclosure (discussed later) represent a minority. The generations of researchers trained in the
1960s and 1970s are representative of periods when university students were heavily associated with
the social and political counter-culture. Our own (the authors’) generation of drug researchers were
university students in the 1990s—a period when recreational drug use peaked, for example, in the UK
(Broadfield, 2017), the US (Johnston et al., 2018) and Australia (Australian Institute of Health and
Welfare, 2017).
To Come Out or Not to Come Out?
It seems that most drug-using drug researchers avoid public disclosure, even if some would prefer to be
able to reflect publicly on the role of drug use in their own work, but deem the risks of doing so too
great. Here we consider the risks of coming out.
The Stigma of the “User” Label: Reasons to Stay in
On one level, the reasons for “staying in” are self-evident—criminal activity is, by definition, behavior
deemed so unacceptable to society as to be punishable by law. There may be legal ramifications of
drug use disclosure. For example, ayahuasca researchers have been legally pursued following admis-
sions of participation in ayahuasca ceremonies (Tupper & Labate, 2014). Anthropology professor
Ansley Hamid was arrested and dismissed from his university for using heroin, but perhaps more
damagingly, also for using grant money to purchase heroin (Smallwood, 2002).
The risk of criminal penalty may not be a great concern for privileged, well-educated professionals
in industrialized democratic countries who do not generally receive serious punishment for minor
offenses of use or possession. But the threat of formal sanctions covers more than the risk of criminal
penalty: stigma may also result. Goffman (1963, p. 3) defined stigma as “an attribute that others
perceive to be deeply discrediting.” The pathology or deficit discourse (Karlsson, 2010; Mugford,
1991), with its assumptions about drug use and drug users being inherently aberrant, is used to
distinguish between “us” (most people who it is assumed do not take drugs) and “them” (the minority
who take drugs and are assumed to experience problems themselves and pose a problem to society). In
response to the denial of the existence of the subject position of “responsible” or “recreational” drug
taker, many hide their drug use to “pass as normal” (Goffman, 1963) in non-drug using contexts, while
others involved in some treatment or legal systems must identify publicly as “drug users” and may then
become subject to stigma. Drug researchers who take drugs themselves also typically choose to “pass
as normal.” We are aware of academics who have been reprimanded and even dismissed when their
own drug use has become known; fears of job loss or curtailed career opportunities are real. Even
without formal sanctions (but more so with), loss of reputation can follow exposure as “deviant.” As
Deleuze said in concern about Foucault’s public admissions of psychoactive drug use: “what will they
think of us?” (cited in Blackman, 2007; Boothroyd, 2006).
There are many ways that the stigma of being known as an illicit drug user may have negative
impacts for drug researchers. There is the fear of research not being taken seriously by academic peers:
accusations that the influence of drugs themselves (being high, or suffering cravings or withdrawal
symptoms)—or assumptions made about the lifestyles, values and professional standards of “drug
users” (lazy, immoral, dishonest)—may be seen to undermine the rigor, validity, objectivity and
integrity of their work. Further, the groups that drug researchers seek to influence, including law
enforcement, politicians and policy makers, may discount the researcher who has disclosed their drug
consumption as biased or unable to produce objective research (Ross, 2020). Drug researchers who
“come out” risk the charge of “polluted motives” if calls for policy change are interpreted as self-
interested or, at least, lacking in objectivity—not just as “drug activists” with suspect motives, but as
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researchers whose expertise may be compromised by intoxication or assumed longer-term effects of
drug use. In the extreme, they risk providing ammunition for prohibitionists to argue that they and their
evidence should be dismissed or ignored—even if their research meets the highest academic standards.
Elsewhere, carrying the label of “drug user”—and therefore of “criminal” and “deviant”—may
impinge on applications for jobs and promotions, funding, or membership of professional associations.
It may limit invitations to join panels and collaborations, or to give media appearances or invited
papers. Travel to certain countries may become difficult, or even impossible, where disclosures of
criminal records or charges for drug offences may disqualify visa applicants. We note that the extent of
these negative impacts varies greatly by one’s country of residence or citizenship.
Stigma may also impact on teaching and on affiliated universities’ reputations. Being on record as a
person who uses drugs could undermine credibility with students (as well as teaching colleagues), but
may also negatively influence prospective students—and their parents. While academics may be able
to convince their students of the benefits of honest and open discussion, and the importance of
reflexivity in the process of research and knowledge development, they need time with these students
to go through the arguments and to deal with initial prejudices. If prospective students—or parents—
form a judgment in advance based on the public knowledge that professor X is, or has been, a “drug
user,” then those students may choose—or be encouraged to choose—a different university for their
studies. And while sound academic arguments and calls for academic freedom may carry some weight
in defending choices of research topics and approaches to teaching, university managers may show
little sympathy to academics suspected of undermining recruitment and related income streams.
Other potential impacts of personal drug disclosure include expulsion or being barred from clubs
and societies, social ostracization, profiling or monitoring by police or other agencies, involvement of
local social services agencies (which may result in children being taken into care), and the impact of
stigma by association on friends and family, for example children at school being identified and
possibly bullied as the off-spring of someone who has taken drugs (Derkas, 2012; Stringer & Baker,
2015). Stigma also means that researchers who are experiencing problems with drug use might not feel
able to seek help. These potential issues are not confined to drug researchers—they can happen to any
drug taker, as research has shown (Ahern et al., 2007; Fraser et al., 2017; Gray, 2010).
Researchers will inevitably recognize the risk that professional and private lives could be disrupted,
in rather permanent ways. By remaining publicly silent, or at least ambiguous, about drug use status,
researchers get to choose to whom they reveal this part of themselves where it is not a matter of public
record. The threats of stigma and sanction provide a strong incentive toward non-disclosure of drug
use. This means that discussion of the value of coming out about drug use is stifled by legal, moral and
professional fears.
Reflexivity: Are There Good Reasons to Come Out?
Where drug researchers have disclosed drug use, it has tended to be because drug use has been
important to their work in some way. The use of psychoactive drugs by philosophers and social
theorists in the 20th century is well documented, with the list including (but by no means limited
to) Walter Benjamin, Jean-Paul Sartre, Michel Foucault, Gilles Deleuze, Alexander Shulgin, Timothy
Leary and Aldous Huxley. Indeed, before psychedelics hit mainstream culture psychiatrists regularly
used LSD and other psychedelic drugs to further their research into the mind (Pollan, 2018). Moving
further back the list includes Sigmund Freud, William James and Friedrich Nietzsche. Benjamin wrote
a book about his experiences with hashish and about hashish intoxication in France (Blackman, 2007).
Sartre documented his use of the psychedelic mescaline (Riedlinger, 1982). James writes a first-hand
account of taking nitrous oxide in order to better understand the philosophy of Hegel (James, 1882). A
famous trip to Death Valley, California, by Foucault also included a strong LSD trip, arranged for him
by his learned academic friends (Miller, 1993). Foucault recounts the utility of LSD in his
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understanding of Deleuze’s philosophical works, and Boothroyd has argued that psychedelic drug use
by Foucault was associated with a shift in his concept of the self, toward a more relational or con-
nective self (Boothroyd, 2006). Freud famously used cocaine and wrote about its effects (Freud, 1885/
1975).
The fact that psychedelic experiences may facilitate understanding or open up new ways of thinking
in general (as for James and Foucault, for example) should not be overlooked, but our focus here is on
more direct ways that drug use relates to drug research. For those who have discussed this publicly, the
justifications for drug use (and for admitting to drug use) in relation to research are largely instru-
mental. In some cases, self-administration of psychoactive drugs forms an essential part of the research
design, such as Alexander Shulgin’s self-experimentation with a wide range of psychedelic com-
pounds, many of which he himself invented, documented in two volumes written with his wife Ann
regarding phenethylamines (Shulgin & Shulgin, 1992) and tryptamines (Shulgin & Shulgin, 1997).
More commonly, and particularly in qualitative research, drug use is discussed primarily as facilitating
access to research populations. But a researcher’s own drug use can be relevant to all stages of the
scientific process (see Newcombe, 2008, on the self-administration of ketamine).
Drug use and the research process. Personal experiences can suggest research questions, and geographic
and cultural proximities enable contact with potential research subjects. That Patricia and Pete Adler
(Adler, 1993) had a drug-smuggling neighbor was entirely coincidental; convincing him to talk openly
to them and to introduce them to other traffickers depended on their identity as drug takers as central to
building trust. Howard Becker’s (1963) role as a cannabis-smoking jazz musician was instrumental to
his accessing cannabis consumers, but also to developing research questions and theoretical insights.
Jock Young (1971) was a member of the North London drug-using community that he writes about in
The Drugtakers. For others who have come out, and many of those we spoke to who haven’t, their own
membership of (sub-)cultural scenes—their insider status or “privileged access” (Pearson, 1993)—is
central to their work. Shared membership of cultural and social scenes puts research subjects “on the
door-step” of the researcher; the shared experience of drug use gives the researcher a “foot in the door”
(Potter, 2010, 2017). Drug research is conducted with hidden populations who are, with good reason,
suspicious of outsiders. Entry into the research field (e.g., when conducting research within drug-using
subcultures) may be facilitated through this (full or partial) insider status. Subjects of research tend to
fear the negative judgements of outsider researchers, with good reason given the dominant discourses
and stereotypes of people who use drugs (Barratt & Lenton, 2010; Potter & Chatwin, 2011).
Ethnographers not only have to access research populations, they must also get on with them over
extended periods of time and encourage them to open up. That taking drugs can facilitate rapport with
the population being researched is well recognized in the literature. Both Becker and Paul Willis told
Shane Blackman that they smoked cannabis while conducting ethnographic research with jazz musi-
cians and “hippies,” respectively (Blackman, 2007). Subcultural ethnographer Sarah Thornton reports
consuming drugs in a club during her ethnography on club cultures (Thornton, 1995). The Adlers
report consuming marijuana and cocaine during their interactions with drug-dealing networks, arguing
that “[q]uite frankly, it would have been impossible for a nonuser to have gained access to this group to
gather the data presented here” (Adler, 1993, p. 24). A key issue to be negotiated by any ethnographer
is how to successfully enter the field of their research and maintain a legitimate role within it. Black-
man (2007) argues that ethnographers taking drugs with their informants is not just a “research
strategy” used to gain entry or acceptance, but also reflects the rapport already established and their
inclusion in normal group activities. Put simply, researchers need to bond with their subjects, and
taking illegal drugs with others can be a socially bonding activity, just as drinking alcohol, smoking
cigarettes, going for coffee or eating a meal would be.
Familiarity with drug use does more than facilitate access and rapport. Understanding of terminol-
ogy, experiences and cultural reference points, for example, can help direct interviews and allow for
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more natural encounters and richer data. While drug-taking researchers may gain a deeper understand-
ing of the data and reach interpretations and conclusions that may be harder for the non-drug taker to
reach, there is also a distinct risk of confirmation bias (Hodkinson, 2005). On the other hand, a problem
for researchers who capitalize on their drug-taker status during research may be that participants then
assume a degree of shared knowledge and might not offer the more careful and detailed explanations
they would articulate with a non-drug taker. Further, research participants may be less willing to
disclose negative experiences to a “drug positive” researcher, or overemphasize an experience believ-
ing it was what the researcher is interested in. In other cases, presenting as a drug taker may be
interpreted as trying too hard to fit in, decreasing rather than increasing access and rapport.
There are many reasons therefore why researchers might want to reflect, openly, on the impact that
their drug-taking status may have on their work. Drug use may have both positive and negative impacts
on the research process—but either way, acknowledging this positioning and experiential knowledge
openly allows both the researcher and the consumers of their research to judge, and to draw conclu-
sions and criticisms accordingly. While many social researchers may strive for the supposed
“objectivity” of the natural sciences, it is naı̈ve and even dangerous to suggest that objectivity can
be achieved, particularly with qualitative methods. Objectivity might be undesirable, anyway, in
interpretivist epistemologies. Better, academically, is identifying potential sources of subjective bias,
interrogating them and recognizing how they may limit, enhance, or otherwise influence the inter-
pretation and application of findings—and to allow academic peers to do the same. Drug-taking
researchers should therefore be encouraged to conduct regular self-reflection especially around how
their knowledge production through research intersects with their own experiential knowledge.
Despite being so central to the research process, reflection on the realities of observing and
participating in deviant activities during ethnographic research—what Blackman (2007) calls “Hidden
Ethnography”—is often stifled. Blackman himself describes participating in drug use with the group of
mods he was studying, involving a mix of amphetamines followed by cannabis. He describes leaving
out this aspect of the fieldwork when writing up the research only to recount it a decade later in a
reflective piece, noting that he felt these admissions would have “undermined his legitimacy” as an
“aspiring sociological PhD research student” (Blackman, 2007, p. 709). This is not just self-policing by
young researchers. The academic community itself reinforces this sense of caution. For understandable
reasons, mentors urge mentees away from coming out, prioritizing concerns around stigma over the
benefits of reflexivity.
Nevertheless, there are a few good examples of reflexivity by drug-using drug researchers. Adler,
Blackman and others mentioned above have reflected on drug use as part of fieldwork, but others
reflect in much greater depth. Two researchers have more recently discussed in some detail how their
biographical histories of drug use intersected with their research practices: Stephen Wakeman (2014),
who formerly used and traded in heroin and crack cocaine, and Magdalena Harris (2015), who
formerly used heroin, contracted Hepatitis C and underwent successful treatment. Both Wakeman
and Harris reflect on the effects of sharing a biography with their research participants in terms of
biographic-emotive awareness: that is, the connections between the lives of their research participants
and their past experiences were felt in the body, leading to different decisions in fieldwork moments. In
one example, Wakeman did not pursue an overly enthusiastic potential research participant who
invited him to meet in a public place as the interaction reminded him of being assaulted when
attempting to obtain heroin. He found out from others later that this person had indeed intended to
rob or assault him. Harris describes how disclosing her shared identity with participants had a variety
of effects, including eliciting disclosures not made to other researchers in the study who had not
identified themselves this way, for example, regarding needle-sharing practices. When asked about
the discordant information, the participant said, “I knew he wasn’t a drug user and I thought ‘no, he’s
not judging me for something I’ve done, no.’” She also mentions being cold as an interview progressed
and after she pulled down her sleeves, the interviewee commented that she shouldn’t be ashamed of her
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track marks around him. Stigma was something shared and felt, by both researcher and interviewee.
Wakeman and Harris, both with past experiences of injecting and dependent patterns of drug use,
mention a difficult aspect of conducting interviews and ethnography with active drug takers: they
describe vivid dreams about commencing injecting again and an uncomfortable urge to resume use. In
Harris’s case, a gendered encounter with an active drug taker she was interviewing who kept insisting
that she “use crack with him” was a consequence of him knowing her drug use history. Shared
biography can also result in the researcher occupying a potentially more vulnerable position.
For others, the focus of disclosure moves beyond the experience of taking drugs to more broad
reflections on the experience of identifying as someone who consumes drugs. In the journal Psymposia
(a forum for discussing emerging issues related to psychedelics, psychoactive drugs, policy reform,
and harm reduction), a series of articles was published in 2016 on the topic of “coming out psy-
chedelic,” with for and against style debate pieces (see Devenot, 2016). Neşe Devenot, a literary
scholar who has studied psychedelic trip reports as a literary genre, frames coming out as a psychedelic
person within queer theory and the ongoing struggles for civil rights. By invoking identity politics,
Devenot suggests that activism be directed toward addressing the systemic discrimination against
psychedelic use and psychedelic people. Devenot also openly identifies as psychedelic, arguing that
to be psychedelic does not necessarily mean that you take psychedelic drugs (e.g., you can be an
explorer of the mind using different cognitive tools). People who have not used drugs can also identify
as psychedelic allies, supporters of drug law reform and the regulated availability of currently pro-
hibited substances. However, Devenot’s utilization of civil rights framing in the protection of psyche-
delic identity has been criticized as misappropriation, due to the asymmetric risks of coming out
psychedelic in comparison to coming out queer (Kaywin, 2016). We take up some of this critique
later in our discussion of privilege and intersectionality.
In a different context, cultural studies academic Kane Race writes about his own identity as a gay
man who fully participated in the gay party scene, including activities involving sex and drug taking,
and contraction of HIV (Race, 2009). His candidness about his identity and participation in the gay
party scene, the topic of his research, opens up a space for merging autoethnographic insights with
analyses of gay cultures: for example, in his depiction of the way multiple elements in a complex
assemblage form an event such as a dance party (Race, 2014).
For researchers producing knowledge about drugs and drug policy, the public disclosure of their
own experiential knowledge of drug use opens up possibilities for that knowledge to be used as a
resource in a public way, rather than implicitly and covertly as is typically the case today. Reflexive
accounts that flesh out how personal experiences intersect with the knowledge created through
research then become possible. Autoethnography is the most obvious example, but reflexive practice
may be possible and desirable even using research methods in which researchers are traditionally less
likely to analyze their own role in the production of knowledge, such as survey research.
While there are beneficial and challenging aspects to sharing a biography or an identity with
research participants, this identity clashes with the “professional” or “academic” identity also claimed
by researchers. Measham and Moore write about the reluctant reflexivity of researchers in club studies,
noting that many feel the need to obscure or hide their dual roles, and this practice results in a lack of or
only a partial account of the relations between researcher and researched (Measham & Moore, 2006).
The dilemma is captured neatly in this quote from an interview with Charles Grob, who has researched
the beneficial effects of MDMA. When asked if he had ever consumed MDMA, he answered “[m]y
response to that sort of question is usually along the lines of ‘I’m damned if I have and I’m damned if I
haven’t.’ If I have, then my perspective would be discounted due to my own personal use bias, and if I
haven’t, it would be discounted because I would not truly understand the full range of experience the
drug can induce” (Avni, 2002, n.p.).
Psychiatrist Lester Grinspoon is of particular note for illustrating the tensions between being open
about drug use as a valid and valuable part of academic research, and the professional risks faced by the
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researcher who does so. Grinspoon thoroughly documented his own journey into cannabis use, pro-
viding a reflection on the relationship between his drug use and his academic career. Grinspoon’s
initiation into cannabis use arose through a combination of influences from his own academic research
and his personal life. As a psychiatrist, reviewing the medical literature led him to believe that the
harms of cannabis were overstated and its benefits underappreciated. This combined with a belief that
to at least try the drug would make him a more objective researcher than to not do so. Also attracted by
the positive effects of cannabis he had seen from cannabis consumers in both his research and his social
life, he eventually began to experiment with cannabis himself. However, he delayed this initiation for
many years through fear of compromising his standing as an objective expert in the eyes of academic
colleagues and policy makers who frequently called on his expertise (Grinspoon, 2009). After he began
consuming cannabis and feeling morally and professionally compelled to be open about this practice,
Grinspoon experienced some significant negative impacts on his career and his relationship with his
employers, Harvard Medical School (although he retained the title Associate Professor Emeritus with
the institution until his death in June 2020) (Grinspoon, n.d.).
Perhaps the most prominent academic who has disclosed his drug use at the time of writing however
is Carl Hart, a neuroscientist and Professor at Columbia University, who has built his recent career on
arguing that perceived harms from drugs such as heroin, methamphetamine and cocaine are over-
exaggerated. In doing so he has self-identified as a user of heroin (Hart, 2014) and experimented with
drugs such as methamphetamine, experiences which he writes about and draws on when teaching (see
further www.drcarlhart.com). Although he has received a backlash in the press, Hart continues to be
employed as a professor, is invited around the world as an expert on drug use and writes regularly for
the media. Arguably it is his stance that opinions should be “evidence-based” and his ability to provide
suitable evidence, including experiential evidence, that stymies attempts to discredit him both as an
expert and an academic.
Policy and politics. For many academic drug researchers, the role of research is to contribute to policy
developments, as well as to generate knowledge. We have discussed ways that public disclosure by
researchers of their drug use may produce “better” research by highlighting subjectivities and encoura-
ging transparency, but there may be associated drawbacks. Disclosure of drug use may simultaneously
function to reduce or remove a researcher’s status and legitimacy. Opportunities for drug policy reform
by influencing those inside the mechanisms of government may therefore be compromised. That is, the
epistemological privilege we get by positioning ourselves as researchers who are not people who use
drugs, or people who formerly used drugs, can be valuable. Despite insights into drug use that in part
derive from personal experiences, in public, researchers can talk from the privileged position of
academic research. From this position our expertise is more likely to be heard and valued, than if
we were to occupy the “drug user” position. So why might it be important for drug researchers to
publicly disclose their own drug use when it comes to engaging with policy makers and with the public
at large?
Academic researchers often seek impact outside of the academy. For many drug researchers, the
aim is to inform effective and evidence-based drug policies. One particularly important effect of
people who are in positions of relative authority making public disclosures about their drug use is
that by doing so, they widen public perception of what kind of person takes drugs. They weaken the
stereotype by posing as a real and tangible counter-example. These counternarratives indeed challenge
the mainstream narrative of “drug users” or worse “drug abusers” or “junkies”—problematic, un-
productive and weak-willed individuals—the dominant “pathology” discourse mentioned earlier. To
go a step further, some may claim that in their experience, their use of currently prohibited psychoac-
tive substances assists their successful management of their work and their life, as many might more
uncontentiously claim in connection to legal substances like caffeine, alcohol, or prescription drugs.
Ross et al. 277
Our scholarship may be produced to a high standard because of these tools (sometimes called cognitive
tools) (Tupper & Labate, 2014), rather than despite them.
By widening the possible subject positions of “drug user” in policy and public discourse through
disclosure of drug use, researchers may raise the profile of “non-problematic” or “recreational” drug
users within policy discussions, making this pattern of drug use more visible. Even though among
those who use drugs, it is the norm to do so occasionally and without significant health or social or
legal harms, the dominant discourse in policy and public discussion silences this reality (Ross, 2020).
Is it possible that by widening the concept of who uses prohibited substances we can break down the
othering that occurs in public discourse and in public policy? Conversely, by staying quiet about our
use of prohibited substances, do we not perpetuate a false dichotomy between the researcher and the
researched? The very existence of academics with PhDs and jobs who also use prohibited drugs jars
with popular representations of those who use drugs and what the consequences of drug use are. If one
of the assumptions upon which prohibition relies is that drug use is always harmful, public disclosure
becomes a political act that troubles this presupposition. Remaining silent, in contrast, may unwittingly
perpetuate the “othering” gaze and even perpetuate prohibition itself. For scholars who conclude that
prohibition itself is harmful, not “coming out” could be ethically problematic.
However, there is an important calculation to be made here. Increased public awareness of drug use
existing within academia may well contribute to normalization of drug use and the reduction of stigma
around “drug users.” But it may also (the two are not mutually exclusive) lead to a rejection of the
knowledge produced by drug-using researchers—and undermine scientific authority more broadly.
Further, the normalization of recreational/non-dependent use may have the opposite effect and
instead of breaking down barriers, may result in further stigmatization of an already marginalized
group—so-called problematic or dependent drug takers. At the heart of this problem is the fact that the
term “drugs” covers multiple intoxicants and even more reasons and ways to intoxicate oneself. By
normalizing one form of intoxication, for example, cannabis use, there is a danger of stigmatizing other
forms such as cocaine or opiate use. This complexity was highlighted by workshop attendees and
others, who disclosed the use of multiple drugs such as amphetamine, cocaine and psychedelics, but
felt that certain drugs such as cannabis were seen as more normalized, and therefore less stigmatizing
to those who may disclose their use.
Other reasons to come out: Impacts on teaching and personal lives. As well as publishing books and articles
and feeding into policy debates through contributing both evidence and expert opinion, many research-
ers also have a teaching role. The disclosure of drug consumption by lecturers to their students may
have some positive effects. Students who are drug takers themselves may see their teacher as breaking
down a barrier to open discussion of the drugs issue more broadly. It may be possible that students who
hold negative attitudes toward drugs may be more likely to open up to different ideas following
disclosure by a lecturer.
Many of those who teach in higher education will have experienced the challenges of getting
students to talk in seminars. Opening up the possibility of talking about personal experiences may
help overcome these problems. Pedagogical research suggests that teacher self-disclosure more gen-
erally may help motivate students to engage in the classroom context (Cayanus, 2004; Henry &
Thorsen, 2018). At the same time our workshop participants voiced concerns that students may hold
different views about lecturers if they were to come out: they may lose authority of voice in their
research and teaching. In extreme cases the repercussions of disclosure could result in disciplinary
action, complaints from students and parents, and reputational damage.
The benefits of public disclosure of drug use to researchers in their personal lives may appear to be
less compelling, but they can include a reduction in cognitive dissonance about being able to publicly
be who they are, rather than hide parts of themselves, which may therefore include increased psycho-
logical well-being (Devenot, 2016). Individuals who hide aspects of their identities in the world have
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been shown to experience heightened psychological distress (Quinn & Chaudoir, 2009). For research-
ers whose use of psychoactive substances is an integral part of their identities, this distress may be
relieved through such public disclosure. By coming out about drug use through public disclosure, the
prospect of being “outed” by others becomes less of a risk; the researcher is therefore in control of
when, where and how disclosure takes place.
The Parameters of Coming Out
Whether disclosure—and reflection—are advisable for the drug-using drugs researcher will depend on
a range of factors, including who is coming out, what they are coming out about and who they are
coming out to. Privilege and intersectionality are important parameters for consideration, as are the
reasons for wanting to come out and what they hope to achieve. We work through these parameters
below in turn.
Admitting drug use to colleagues in personal interactions is likely easier and safer than coming out
to employers or managers. Previously, coming out in lectures, seminars or conference presentations
where these were unrecorded provided a degree of privacy and plausible deniability; however, in the
current era of instant dissemination of text, photographs and videos via social media—and the increas-
ing ubiquity of video-recording lectures (O’Callaghan et al., 2017)—privacy in these sorts of domains
is no longer a given. Who might be expected to be a consumer of such information, and who might end
up an unforeseen consumer? Coming out in public lectures, or on social media, opens up a wider
potential audience and therefore a greater risk of both negative and positive outcomes. We have
structured the debate here around coming out on the record, particularly in published academic work,
which may, at times, also attract media coverage.
We should also consider what is being disclosed, as different levels of disclosure are likely subject
to a different equation of pros and cons. Admitting to past drug use will be received differently to
admitting current drug use—or future intentions of drug use. Past events can be forgiven—even
presented as, or taken as, mistakes to be addressed in the future. In fact, disclosing former drug taking
by researchers who are now “clean” or “sober” may confer a kind of epistemological privilege not
afforded to current drug takers. It may be no surprise that of the limited instances of researchers
disclosing drug consumption in their publications, most refer to former use, as was the situation with
both Wakeman and Harris, discussed above. Researchers who cast their former drug use as proble-
matic—for example as “addiction”—may elicit sympathy or even praise, especially where the
researcher has sought treatment. This redemption narrative is unavailable to current drug takers—and
may be unwelcome for those who do not see either their past or their current drug use as problematic.
The legal status of the substance(s) in question is, of course, relevant. Where substances used in
relation to research are not (yet) prohibited, it is easier to report taking an autoethnographic or even
psychonautic approach (Newcombe & Johnson, 1999). For example, Shulgin had permission from the
US government to manufacture and use otherwise illegal psychoactive substances (Shulgin & Shulgin,
1992, 1997). Newcombe conducted autoethnographic research on the drug ketamine before it was
prohibited (Newcombe, 2008). One of the first published papers on the then-legal synthetic cannabi-
noid drugs contained a self-administration and discussion of the drug’s effects (Auwärter et al., 2009).
Such disclosures do not carry the risk of criminal justice sanctions, although many other aspects of
stigma may apply to behaviors considered immoral or deviant even if not illegal.
Additional complexity relates to the seriousness of the activity admitted to, whether reflecting legal
codes or public perceptions. It is undoubtedly easier to admit to occasional use of cannabis (a Class B
drug under UK law, and a legal drug in some jurisdictions) than use of substances perceived to be
“harder” (such as the Class A drugs heroin or cocaine) or to heavier or more frequent patterns of
consumption. Admitting to supply and production related offences will be more challenging than
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admitting to possession and use, even though most drug consumers, by virtue of freely giving drugs to
others, engage in drug supply activities (Measham et al., 2001).
The parameters of coming out may also change depending on the researcher’s disciplinary and
methodological context. Anthropologists and sociologists may be less stigmatized than researchers
working in other disciplinary areas, like law, health or policy studies. Ethnographers, in particular, and
qualitative researchers in general may have more leeway than quantitative researchers. Drug use as
described by Shulgin, Grinspoon, Hart and other psychonauts may be perceived differently, even
legitimately as a product of their line of work. Seniority may also be a factor. Established col-
leagues—especially those with tenure—may have more leeway than early career researchers or PhD
students. Or it may be the other way around, where senior colleagues in management positions have
less freedom to disclose than junior colleagues willing to push some boundaries.
What are the implications of privilege and intersectionality for decisions about whether and how to
disclose drug taking and drug use identities? Feminist Peggy McIntosh introduced the concept “white
privilege,” alongside male privilege, to describe the typically invisible set of advantages enjoyed by
people occupying dominant social categories. In a reflection upon the growth of Privilege Studies in
2012, McIntosh introduces a metaphor of privilege as a bank account: one that individuals receive at
birth, but didn’t ask for or achieve, but that continually refills throughout lifetimes. In contrast to
people born with identities carrying disadvantage, people born into privilege can choose to draw down
on their bank account to work against injustice, without losing much (McIntosh, 2012). The concept of
intersectionality, first coined by Crenshaw (1991), is useful here as it requires us to attend to the
complex and intersecting categories of oppression that people experience (Davis, 2008, p. 68).
Through intersectionality we see that “race, class, gender, sexuality, ethnicity, nation, ability, and age
operate not as unitary, mutually exclusive entities, but rather as reciprocally constructing phenomena”
(Collins, 2015, p. 1). We should not, therefore, consider the stigma of a drug-using identity in isolation
from other “categories of difference” (Devenot, 2016). What does this mean for researchers who
typically face fewer intersecting categories of oppression, and so have relatively more privilege and
power? “Problem drug takers” are a particularly stigmatized group. It may therefore be more urgent for
people with privilege to come out publicly about drug use, because it is significantly more difficult for
people already battling daily discriminations to put themselves on the line even further. On the other
hand, public disclosures of “responsible” drug use by those who occupy privileged positions may
further reinforce stereotypes of problem drug takers. It may not be easy to establish how privileged
academic researchers coming out about their drug use can guard against the possibility of this perverse
outcome of their political action.
Finally, but perhaps most importantly, there is the question of “why?” Coming out as a drug
consumer may be more acceptable when it is clear how the disclosure relates to academic principles
or activist ideals. Critical reflection on the role of drug use in the research process or philosophical
framework may carry less stigma than admissions that seem irrelevant or self-indulgent. On the other
hand, if the goal is de-stigmatization of drug use or change of drug policy in reflection of the fact that
drug takers can be successful professionals, then the justifiable contexts to coming out may be quite
different.
Concluding Thoughts
Broadly speaking, the arguments for and against coming out can be summarized in terms of stigma and
reflexivity. To admit to drug use is to admit to activity which many may consider immoral and which
society officially disapproves of through criminalization. The label “drug user” carries stigma, which
may threaten academics’ reputations, their ability to contribute to scientific and policy debates, and
their very careers. It may also seriously impact their personal lives. But to not come out is to miss a
valuable opportunity for reflexivity, and for the improvements to scientific knowledge and evidence-
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based policy this potentiates. We also miss an opportunity to challenge those very stigmas around drug
use that stifle reflexivity in the first place—and that are so often reinforced by policies that seek to
punish, marginalize or further stigmatize people who use drugs.
Reflexive research practice involves researchers interrogating all aspects of the context of knowl-
edge construction, including the personal and social location of researchers themselves (Gough &
Finlay, 2003). When as researchers we hide our lived experiences with drugs from the consumers of
our research, we are impeded in our capacity to be candid about how we decide on particular research
questions, make sense of our data, and draw conclusions. Researchers disclosing their own drug
consumption take considerable risks. But to the extent that they maintain their silence—and so their
privilege—they contribute to the problem of stigma by reproducing it, such that drug consumers
remain “other.” Even so, it is important to maintain space and support for positive evaluations of not
coming out. The paradox of presumptions navigated by people who hold a hidden potentially-
stigmatizing identity (see Adams, 2010), and the effects of privilege and intersectionality, cannot be
assumed to play out the same way for everyone.
Our article is not a confessional, nor do we claim in it that drug use is rife among professional drug
researchers. Rather, in this article, we call for honest reflection within the field. Some drug researchers
do have personal experiences of drug use, and these lived experiences undoubtedly have some impact
upon their professional work. We hope we have demonstrated that there are strong arguments for
reflecting on this issue where it is appropriate and relevant to do so. These arguments include those
embedded in methodological and epistemological positions (where reflections on drug use are a
necessary part of the scientific process) and those more overtly aligned to activism (where coming
out may be seen primarily as a political act)—not that these perspectives are mutually exclusive.
However, we must recognize the very real risks that coming out about stigmatized or illegal activities5
might pose for professional and personal lives. To come out or to not come out is a personal decision
that will depend on a wide range of individual and contextual variables. We hope here to do no more
than start a debate; we call not for disclosure en masse, but for reflection—which may still mostly take
place in private, but which we hope may increasingly emerge in public.
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Notes
1. Although our discussion here is focused on illegal drugs, many of the issues also apply to patterns of legal drug
use, including alcohol, prescription medications and tobacco smoking – and to other behaviors which may be
illegal or perceived as inappropriate or immoral.
2. Many of the points raised are also relevant to illicit drug use in other areas of academia, other professions and
occupations, and among the populace at large (Spirovska, 2017). However, there are certain issues that are
particularly relevant and some that are specific to drug use among drug researchers, and it is this group that we
focus on here.
3. For example, the 2020 campaign “Thank you plant medicine” asks people who have benefited from psychoac-
tive plants to “come out” publicly about their experiences, see https://thankyouplantmedicine.com/
4. Accounts of academics and intellectuals taking drugs such as cocaine and opiates before they were illegal go
back much further.
5. Drug use is our main concern here, but parallels can be drawn with numerous other activities.
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Auwärter, V., Dresen, S., Weinmann, W., Müller, M., Pütz, M., & Ferreirós, N. (2009). “Spice” and other herbal
blends: Harmless incense or cannabinoid designer drugs? Journal of Mass Spectrometry, 44, 832–837.
Avni, S. (2002, 13 September). Ecstasy begets empathy. Salon. https://www.salon.com/2002/09/12/grob_
interview/
Barratt, M. J., & Lenton, S. (2010). Beyond recruitment? Participatory online research with people who use drugs.
International Journal of Internet Research Ethics, 3, 69–86.
Becker, H. S. (1963). Outsiders: Studies in the sociology of deviance. The Free Press.
Blackman, S. J. (2016). The emotional imagination: Exploring critical ventriloquy and emotional edgework in
reflexive sociological ethnography with young people. In S. J. Blackman & M. Kempson (Eds.), The sub-
cultural imagination: Theory, Research and reflexivity in contemporary youth cultures (pp. 65–79). Routledge.
Blackman, S. J. (2007). “Hidden ethnography”: Crossing emotional borders in qualitative accounts of young
people’s lives. Sociology, 41, 699–716.
Boothroyd, D. (2006). Culture on drugs: Narco-cultural studies of high modernity. Manchester University Press.
Broadfield, D. (2017). Drug misuse: Findings from the 2016/17 Crime Survey for England and Wales. Home
Office.
Cayanus, J. L. (2004). Effective instructional practice: Using teacher self-disclosure as an instructional tool.
Communication Teacher, 18(1), 6–9.
Collins, P. H. (2015). Intersectionality’s definitional dilemmas. Annual Review of Sociology, 41, 1–20.
Crenshaw, K. (1991). Mapping the margins: Intersectionality, identity politics, and violence against women of
color. Stanford Law Review, 43(6), 1241–1299.
Davis, K. (2008). Intersectionality as buzzword: A sociology of science perspective on what makes a feminist
theory successful. Feminist Theory, 9(1), 67–85.
Derkas, E. (2012). “Don’t let your pregnancy get in the way of your drug addiction”: CRACK and the ideological
construction of addicted women. Social Justice, 38(3), 125–144.
282 Contemporary Drug Problems 47(4)
Devenot, N. (2016). Coming out of the psychedelic closet: Psychedelics and identity politics. Psymposia
Magazine. https://www.psymposia.com/coming-out-of-the-psychedelic-closet/
Ettore, E. (2017). Feminist autoethnography, gender, and drug use: “Feeling about” empathy while “storying
the I.” Contemporary Drug Problems, 44(4), 356–374.
Fraser, S., Pienaar, K., Dilkes-Frayne, E., Moore, D., Kokanovic, R., Treloar, C., & Dunlop, A. (2017). Addiction
stigma and the biopolitics of liberal modernity: A qualitative analysis. International Journal of Drug Policy,
44, 192–201.
Freud, S. (1975). The cocaine papers (R. Byck, Ed.). Plume. (Original work published 1885)
Fricker, M. (2013). Epistemic justice as a condition of political freedom? Synthese, 190(7), 1317–1332.
Goffman, E. (1963). Stigma: Notes on the management of spoiled identity. Prentice Hall.
Gough, B., & Finlay, L. (Eds.). (2003). Reflexivity: A practical guide for researchers in health and social sciences.
Blackwell.
Grasswick, H. (2018) Understanding epistemic trust injustices and their harms. Royal Institute of Philosophy
Supplement, 84, 69–91.
Gray, R. (2010). Shame, labeling and stigma: Challenges to counseling clients in alcohol and other drug settings.
Contemporary Drug Problems, 37, 685–703.
Grinspoon, L. (2009). A cannabis odyssey: To smoke or not to smoke. http://marijuana-uses.com/to-smoke-or-not-
to-smoke-a-cannabis-odyssey/
Grinspoon, L. (n.d.). Harvard, marijuana and me. http://rxmarijuana.com/harvard_marijuana_me.htm
Haraway, H. (1988) Situated knowledges: The science question in feminism and the privilege of partial perspec-
tive. Feminist Studies, 14, 575–599.
Harding, S. (1986). The science question in feminism. Cornell University Press.
Harris, M. (2015). “Three in the room”: Embodiment, disclosure, and vulnerability in qualitative research.
Qualitative Health Research, 25(12), 1689–1699.
Hart, C. (2014). High price: Drugs, neuroscience, and discovering myself. Harper.
Hartsock, N. C. M. (1987). The feminist standpoint. In S. Harding (Ed.), Feminism & Methodology (pp. 157–180).
Indiana University Press.
Henry, A., & Thorsen, C. (2018). Teachers’ self-disclosures and influences on students’ motivation: A relational
perspective. International Journal of Bilingual Education and Bilingualism. https://doi.org/10.1080/13
670050.2018.1441261
Hodkinson, P. (2005). “Insider research” in the study of youth cultures. Journal of Youth Studies, 8, 131–149.
Huxley, A. (1954). The doors of perception. Chatto & Windus.
James, W. (1882). Subjective effects of nitrous oxide. Mind, 7.
Johnston, L. D., Miech, R. A., O’Malley, P. M., Bachman, J. G., Schulenberg, J. E., & Patrick, M. E. (2018).
Monitoring the Future national survey results on drug use, 1975-2017: Overview, key findings on adolescent
drug use. Institute for Social Research, The University of Michigan.
Karlsson, P. (2010). Alternatives to the deficit model of adolescent drug use. In T. Decorte & J. Fountain (Eds.),
Pleasure, pain and profit. European perspectives on drugs (pp. 21–34). Pabst Science Publishers.
Kaywin, E. (2016). The asymmetric risk of coming out in queer and psychedelic communities. Psymposia
Magazine. https://www.psymposia.com/magazine/asymmetric-risk/
Lancaster, K. (2016). Performing the evidence-based drug policy paradigm. Contemporary Drug Problems, 43(2),
142–153.
Leary, T., Metzner, R., & Alpert, R. (1964). The psychedelic experience: A manual based on the Tibetan book of
the Dead. Citadel.
Lumsden, K. (2019). Reflexivity. Theory, method, and practice. Routledge.
McDonald, J. (2013). Coming out in the field: A queer reflexive account of shifting researcher identity.
Management Learning, 44(2), 127–143.
McIntosh, P. (2012). Reflections and future directions for privilege studies. Journal of Social Issues, 68(1),
194–206.
Ross et al. 283
Measham, F., Aldridge, J., & Parker, H. (2001). Dancing on drugs: Risk, health and hedonism in the British club
scene. Free Association Books.
Measham, F., & Moore, K. (2006). Reluctant reflexivity, implicit insider knowledge and the development of club
studies. In B. Sanders (Ed.), Drugs, clubs and young people. Sociological and public health perspectives (pp.
12–25). Ashgate.
Miller, J. E. (1993). The passion of Michel Foucault. Harvard University Press.
Mugford, S. K. (1991). Controlled drug use among recreational users: Sociological perspectives. In N. Heather,
W. R. Miller & J. Greeley (Eds.), Self-control and the addictive behaviours (pp. 243–261). Maxwell
MacMillan Publishing.
Newcombe, R. (2008). Ketamine case study: The phenomenology of a ketamine experience. Addiction Research
and Theory, 16, 209–215.
Newcombe, R., & Johnson, M. (1999, November). Psychonautics: A model and method for exploring the sub-
jective effects of psychoactive drugs [Paper presentation]. Club Health 2000, First International Conference on
Nightlife and Substance Use, Royal Tropical Institute. https://pdfs.semanticscholar.org/0869/
8826dd5500670c4cdb7fdece8609bdb03f22.pdf
O’Callaghan, F. V., Neumann, D. L., Jones, L., & Creed, P. A. (2017). The use of lecture recordings in higher
education: A review of institutional, student, and lecturer issues. Education and Information Technologies,
22(1), 399–415.
O’Gorman, A., Potter, G. R., & Fountain, J. (Eds.). (2016). Evidence in European social drug research and drug
policy. Pabst.
Pearson, G. (1993). Talking a good fight: Authenticity and distance in the ethnographer’s craft. In D. Hobbs &
T. May (Eds.), Interpreting the field: Accounts of ethnography (pp. vii–xvii). Clarendon Press.
Pollan, M. (2018). How to change your mind: What the new science of psychedelics teaches us about conscious-
ness, dying, addiction, depression, and transcendence. Penguin.
Potter, G. R. (2010). Weed, need and greed: A study of domestic cannabis cultivation. Free Association Books.
Potter, G. R. (2017). Real gates to virtual fields: Integrating online and offline ethnography in studying cannabis
cultivation and reflections on the applicability of this approach in criminological ethnography more generally.
Methodological Innovations, 10(1), 2059799117720609.
Potter, G. R., & Chatwin, C. (2011). Researching cannabis markets online: Some lessons from the virtual field. In
J. Fountain, V. A. Frank & D. J. Korf (Eds.), Markets, methods and messages. Dynamics in European drug
research (pp. 69–84). Pabst Science Publishers.
Quinn, D. M., & Chaudoir, S. R. (2009). Living with a concealable stigmatized identity: The impact of anticipated
stigma, centrality, salience, and cultural stigma on psychological distress and health. Journal of Personality
and Social Psychology 97(4), 634–651.
Race, K. (2009). Pleasure consuming medicine: The queer politics of drugs. Duke University Press.
Race, K. (2014). Complex events: Drug effects and emergent causality. Contemporary Drug Problems, 41(3),
301–334.
Riedlinger, T. J. (1982). Sartre’s rite of passage. Journal of Transpersonal Psychology, 14(2), 105–123.
Ross, A. (2016). Getting voices to the policy table: The role of drug consumers and experiential knowledge in
measurements of drug related harm [Paper presentation]. Tenth Annual Conference of the International
Society for the Study of Drug Policy. https://www.academia.edu/26014962/Getting_Voices_to_the_Policy_
Table_The_role_of_drug_consumers_and_experiential_knowledge_in_measurements_of_drug_related_harm
Ross, A. (2020). Drug users as stakeholders in drug policy: Questions of legitimacy and the silencing of the
“happy” drug user. In A. Buxton, L. Burger, & G. Margo, (Eds.), The impact of global drug policy on women:
Shifting the needle. Emerald Publishing.
Sedgwick, E. K. (1990). Epistemology of the closet. University of California Press.
Shulgin, A. T., & Shulgin, A. (1992). PiHKAL: A chemical love story. Transform Press.
Shulgin, A. T., & Shulgin, A. (1997). TiHKAL: The continuation. Transform Press.
284 Contemporary Drug Problems 47(4)
Smallwood, S. (2002). Crossing the line: A heroin researcher partakes and pays the price. The Chronicle of Higher
Education, 49(9), A.8.
Spirovska, N. (2017, October 27). Everybody’s on drugs, so let’s stop pretending otherwise. Junkee. http://junkee.
com/everybodys-on-drugs/132919
Stringer, K. L., & Baker, E. H. (2015). Stigma as a barrier to substance abuse treatment among those with unmet
need: An analysis of parenthood and marital status. Journal of Family Issues, 39(1), 3–27.
Thornton, S. (1995). Club cultures: Music, media and subcultural capital. University Press of New England.
Travers, S. D. (2018). ‘Coming out of the closet’ – examining a metaphor. Annals of the International Commu-
nication Association, 42(3), 145–154.
Tupper, K. W., & Labate, B. W. (2014). Ayahuasca, psychedelic studies and health Sciences: The politics of
knowledge and inquiry into an Amazonian plant brew. Current Drug Abuse Reviews, 7(2), 71–80.
United Nations Office on Drugs and Crime. (2017). 2017 world drug report. United Nations.
Wakeman, S. (2014). Fieldwork, biography and emotion: Doing criminological autoethnography. British Journal
of Criminology, 54(5), 705–721.
Young, J. (1971). The drugtakers. Paladin.
Author Biographies
Anna Ross is a postgraduate candidate at the University of Edinburgh. Her thesis explores the narratives within
Scottish drug policy communities, with a particular focus on governance and participation. She also hosts the
Scottish Drugs Policy Conversations, a deliberative group of stakeholders exploring the viability of civic led drug
policy deliberation.
Gary R. Potter is a reader in Criminology at Lancaster University Law School. He has been researching drug
markets for 20 years, with particular interests in cannabis cultivation and social supply.
Monica J. Barratt is a senior research fellow at the Social and Global Studies Centre, RMIT University,
Melbourne, Australia, and visiting fellow at the National Drug and Alcohol Research Centre, UNSW. She leads
a program of research understanding and responding to new illicit drug trends driven by digital connectivity,
including digital drug trading and the emergence and regulation of new psychoactive substances.
Judith A. Aldridge is professor of Criminology in the Department of Criminology, University of Manchester. For
over 25 years, she has written on drug use, drug markets and drug policy. Research in recent years has focussed on
virtual drug markets.
Ross et al. 285
